Pharming Group (Netherlands) Performance
| PHARM Stock | EUR 0.70 0.01 1.41% |
The company holds a Beta of -0.1, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pharming Group are expected to decrease at a much lower rate. During the bear market, Pharming Group is likely to outperform the market. Pharming Group NV right now holds a risk of 3.14%. Please check Pharming Group NV total risk alpha, as well as the relationship between the skewness and day median price , to decide if Pharming Group NV will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pharming Group NV has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Pharming Group is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 167.1 M | |
| Total Cashflows From Investing Activities | -21.3 M |
Pharming |
Pharming Group Relative Risk vs. Return Landscape
If you would invest 72.00 in Pharming Group NV on August 24, 2024 and sell it today you would lose (2.00) from holding Pharming Group NV or give up 2.78% of portfolio value over 90 days. Pharming Group NV is generating 0.0044% of daily returns and assumes 3.1382% volatility on return distribution over the 90 days horizon. Simply put, 27% of stocks are less volatile than Pharming, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pharming Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharming Group's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharming Group NV, and traders can use it to determine the average amount a Pharming Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0014
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PHARM |
Estimated Market Risk
| 3.14 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pharming Group is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharming Group by adding Pharming Group to a well-diversified portfolio.
Pharming Group Fundamentals Growth
Pharming Stock prices reflect investors' perceptions of the future prospects and financial health of Pharming Group, and Pharming Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharming Stock performance.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 683.14 M | |||
| Shares Outstanding | 652.41 M | |||
| Price To Earning | 22.31 X | |||
| Price To Book | 3.85 X | |||
| Price To Sales | 3.57 X | |||
| Revenue | 167.68 M | |||
| EBITDA | 41.22 M | |||
| Cash And Equivalents | 63.89 M | |||
| Cash Per Share | 0.10 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 84.60 % | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.04 X | |||
| Total Asset | 350.55 M | |||
About Pharming Group Performance
By analyzing Pharming Group's fundamental ratios, stakeholders can gain valuable insights into Pharming Group's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharming Group has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharming Group has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. PHARMING GROUP operates under Biotechnology classification in Netherlands and is traded on Amsterdam Stock Exchange. It employs 183 people.Things to note about Pharming Group NV performance evaluation
Checking the ongoing alerts about Pharming Group for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharming Group NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharming Group NV has some characteristics of a very speculative penny stock | |
| Pharming Group NV had very high historical volatility over the last 90 days | |
| Pharming Group NV has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations |
- Analyzing Pharming Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharming Group's stock is overvalued or undervalued compared to its peers.
- Examining Pharming Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharming Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharming Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharming Group's stock. These opinions can provide insight into Pharming Group's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharming Stock analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |